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TO THE EDITOR
The melanoma field has been invigo-
rated by the recent presentation of
phase I clinical trial results using an
inhibitor, PLX4032, that elicits mutant
B-RAF selective effects (Flaherty et al.,
2009). The majority of mutant B-RAF
melanoma patients who were adminis-
tered PLX4032 showed clinical re-
sponses within 2 weeks and experi-
enced an approximately 7–8 month
progression-free survival benefit. In a
field with a dearth of effective treat-
ments for advanced disease, the rapid
progression from identification of
B-RAF mutations in 2002 (Davies et al.,
2002) to development of a clinically
effective drug against mutant B-RAF is a
strong argument for the development of
targeted therapies. However, a series of
recent publications have uncovered
novel mechanisms that paradoxically
activate the RAF pathway in the
presence of clinically relevant B-RAF
inhibitors (Halaban et al., 2010;
Hatzivassiliou et al., 2010; Heidorn
et al., 2010; Poulikakos et al., 2010).
Furthermore, they highlight that patient
selection is likely to be critical to
prevent adverse effects of RAF inhibi-
tors in a subset of melanoma patients.
In the canonical receptor tyrosine
kinase signaling pathway, RAF serine/
threonine kinases are recruited to
the membrane by RAS and activated
by phosphorylation. Three RAF iso-
enzymes exist: A-RAF, B-RAF, and
C-RAF. RAFs form both homodimers
and heterodimers but, notably, it is the
heterodimer complex that exhibits in-
creased activity even when one of the
RAF protomers in the complex is
kinase-dead (Rushworth et al., 2006;
Ritt et al., 2010). RAFs activate the
MAPK/ERK kinase (MEK)/extracellular
signal-regulated kinase 1/2 (ERK1/2)
pathway, which promotes prolifer-
ation, migration, and survival in tumor
cells (Michaloglou et al., 2008). B-RAF
mutations are found in approximately
50% of melanomas; the most frequent
mutation encoding a valine to glutamic
acid substitution at amino-acid 600
(B-RAFV600E) results in a constitutively
active B-RAF kinase (Davies et al.,
2002). An inhibitor, PLX4720 (a close
structural analog of PLX4032), potently
inhibits the growth of B-RAFV600E mel-
anoma cells in vitro and in tumor
xenograft models (Tsai et al., 2008).
Activating RAS mutations are
present in approximately 15–25% of
melanomas (N-RAS 20%, K-RAS 2%)
in a mutually exclusive manner to
B-RAFV600E mutations (http://www.sanger.
ac.uk/genetics/CGP/cosmic). Four recent
papers show that several structurally
distinct B-RAF inhibitors including
PLX4032/4720 induce a paradoxical
activation of MEK/ERK1/2 signaling in
mutant N-RAS melanoma cells (Halaban
et al., 2010; Hatzivassiliou et al., 2010;
Heidorn et al., 2010; Poulikakos et al.,
2010). Similar effects are also observed
in some wild-type B-RAF/wild-type RAS
melanoma cells, presumably due to high
basal levels of active RAS, and in mutant
K-RAS cell lines. Activation of RAF
signaling by RAF inhibitors has been
observed previously (Hall-Jackson et al.,
1999; King et al., 2006), but now
the underlying mechanisms have been
delineated.
The overarching model is that GTP-
loaded RAS promotes RAF dimerization
and that, within RAF dimer complexes,
a drug-inactivated RAF isoenzyme
transactivates a C-RAF partner. The
activated C-RAF partner, in turn, phos-
phorylates and activates the MEK/ERK1/
2 pathway (Figure 1). Some differences
in the underlying mechanisms between
the studies are described, most notably
the target isoform of the RAF inhibitor.
Conversely, Poulikakos et al. (2010)
and Hatzivassiliou et al. (2010) show
that PLX4720/4032 activation occurs
through the formation of C-RAF/C-RAF
dimers and can occur in the absence
of B-RAF. By contrast in the Heidorn
et al. (2010) model, C-RAF is activated
by an inactive B-RAF. Consistent with
this second model, a naturally occur-
ring kinase-deficient B-RAF mutant
(B-RAFD594V), which is found in a small
subset of melanomas, interacts with
C-RAF and activates MEK/ERK1/2
signaling. The differences are based on
results obtained with ‘‘gatekeeper’’
mutations that sterically prevent inhibi-
tor binding to the active site in RAF.
Poulikakos et al. (2010) and Hatzivas-
siliou et al. (2010) show that the ‘‘gate-
keeper’’ threonine 421 to asparagine of
C-RAF (C-RAFT421N) prevents the cross-
activation of C-RAF by preventing the
drug-induced translocation of C-RAF to
the plasma membrane. Alternatively,
Heidorn et al. (2010) show that ERK1/2
activation is prevented by a gatekeeper
mutation in B-RAF (B-RAFT529N). A
likely difference may be related to the
specific drugs used. PLX4720 induces a
shift in the aC-helix of B-RAF and
actually destabilizes the interaction
between B-RAF and C-RAF (Hatzivassi-
liou et al., 2010). In agreement with
this, Halaban et al. (2010) did not
detect B-RAF/C-RAF heterodimers in
the presence of PLX4032. By contrast,
other ATP competitive inhibitors, such
as 885-A and GDC-0879, stabilized the
interaction between B-RAF and C-RAF
(Hatzivassiliou et al., 2010; Heidorn
et al., 2010). It is noteworthy thatAbbreviations: ERK1/2, extracellular signal-regulated kinase 1/2; MEK, MAPK/ERK kinase
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although PLX4032/4720 was originally
described as a selective mutant B-RAF
inhibitor, recent analysis shows it
also inhibits both C-RAF and A-RAF in
in vitro kinase assays (Hatzivassiliou
et al., 2010; Poulikakos et al., 2010).
The mutant selective effects observed
in cells and patients are likely due
to the lower affinity of mutant B-RAF
for ATP compared to wild-type forms
of B-RAF and C-RAF (Hatzivassiliou
et al., 2010).
A second difference is the involve-
ment of RAS. Hatzivassiliou et al.
(2010) and Heidorn et al. (2010) use
knockdown and dominant negative
approaches to show that the 885-A-
and GDC-0879-induced activation of
MEK is dependent on RAS. Although
Poulikakos et al. (2010) show that
mutant RAS enhances PLX4032-
induced activation of MEK, they addi-
tionally show that an N-terminal
deletion mutation of C-RAF, which is
independent of RAS, is activated by
PLX4032/4720. Similarly, Halaban
et al. (2010) show that C-RAF with a
mutation in the RAS binding domain
remains activatable by PLX4032.
These studies again point to subtle
differences in the mechanisms of acti-
vation between the inhibitors used and
indicate that both RAS-dependent and
RAS-independent mechanisms likely
contribute to PLX4032/4720-induced
activation.
Although mechanistic details differ,
the underlying message is that in the
wrong genotypic setting, B-RAF inhibi-
tors lead to inappropriate activation of
MEK/ERK1/2 signaling. This inappropri-
ate signaling has some profound effects
on cellular homeostasis. Several
wild-type B-RAF and RAS or wild-type
B-RAF and mutant RAS cell lines
showed hyperproliferation upon
treatment with inhibitors PLX4720 and
GDC-8079 (Hatzivassiliou et al., 2010).
In early stage primary melanomas,
treatment with PLX4720/4032 resulted
in increased cellular motility (Halaban
et al., 2010). Furthermore, the progres-
sion to melanoma was observed
in melanocytes from transgenic mice
expressing both kinase-defective
B-RAF (B-RAFD954A) and constitutively
activated KRAS (KRASG12D) (Heidorn
et al., 2010).
Overall, these studies emphasize the
importance of genotypically stratifying
melanoma patients before enrollment
on B-RAF inhibitor trials to reduce
unwanted side effects. The inappropri-
ate activation of RAF kinase activity
provides a mechanistic basis for why
approximately 20% of patients enrolled
in clinical trials for PLX4032 developed
keratoacanthomas and squamous cells
carcinomas (Flaherty et al., 2009). They
also provide guidance to the design of
novel therapeutics to inhibit oncogenic
B-RAF kinase activity with reduced side
effects to the patients.
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Figure 1. Model figure for B-RAF inhibitor-mediated activation of the C-RAF/MEK/ERK pathway in non-mutant B-RAF melanoma cells. In wild-type and
mutant N-RAS cells, B-RAF and C-RAF are recruited to the plasma membrane and associate with activated RAS (RAS-GTP). Formation of B-RAF/C-RAF
heterodimers or C-RAF/C-RAF homodimers leads to activation of the MEK/ERK1/2 pathway. Treatment with ATP-competitive RAF inhibitors promotes the
formation of RAF dimers. In one scenario, binding of the RAF inhibitor to B-RAF leads to the formation of B-RAF/C-RAF heterodimers that contains an inactivated
B-RAF and a hyperactivated C-RAF. In the second scenario, binding of the RAF inhibitor to C-RAF results in the formation of C-RAF/C-RAF homodimers that
contain one inactivated C-RAF and one hyperactivated C-RAF. In either scenario, MEK/ERK1/2 signaling is hyperactivated. We note that some experiments with
PLX4032/4720 indicate RAS-independent mechanisms of activation, adding further complexity to this model.
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TO THE EDITOR
Uniparental disomy (UPD) is a condi-
tion in which two chromosomes of the
same pair are inherited in whole or in
part from only one parent. There are
two types of UPD: uniparental isodis-
omy and uniparental heterodisomy.
The former refers to two identical
copies of a single homolog of a
chromosome from one parent, and the
latter indicates two different chromo-
some homologs from one parent. UPD
can lead to an abnormal phenotype
when isodisomy for a chromosome
carrying a mutation for an autosomal-
recessive disease gene results in homo-
zygosity for the mutation.
Epidermolysis bullosa (EB) is a col-
lection of heterogeneous disorders, in
which congenital skin fragility leads to
separation of the dermo-epidermal junc-
tion. EB has been subdivided into three
major groups and one minor group,
based on the level of blister formation:
EB simplex, junctional EB, (JEB), dys-
trophic EB, and Kindler syndrome
(Fine et al., 2008). Mutations in 14
different genes have been identified as
underlying EB subtypes (Fine et al.,
2008; Groves et al., 2010). Among
them, mutations in the gene encoding
a6 integrin subunit (ITGA6) or b4
integrin subunit (ITGB4) are responsible
for one rare subtype of JEB: JEB
associated with pyloric atresia (JEB-
PA). JEB-PA is inherited autosomal
recessively and is characterized by
generalized blistering and occlusion of
the pylorus at birth, which usually leads
to early demise. Most patients with JEB-
PA have mutations in ITGB4, and more
than 60 ITGB4 mutations have been
identified in JEB-PA cases.
The proband was the first child of
nonconsanguineous healthy parents.
There was no family history of bullous
diseases. The child was born by cesar-
ean section after a 35-week gestation
because of polyhydramnion and had
a birth weight of 1916 g and a birth
length of 46.5 cm. Clinical manifesta-
tions of the proband included
extensive blistering, especially on the
extremities (Figure 1a). Routine abdom-
inal X-ray demonstrated pyloric atresia
(PA) (Figure 1b). No abnormalities
other than skin fragility and PA were
apparent. The proband died of sepsis 2
months after birth.
Immunofluorescence analysis re-
vealed an absence of the b4 integrin
subunit in skin specimens from the
proband (Figure 1c–f). Expression of a6
integrin subunit and plectin was reduced
in proband skin samples (Figure 1g
and h). Immunostaining for BP230,
laminin 332, and type VII collagen
revealed normal linear-labeling pat-
terns (Figure 1i–k).
Mutational analysis of all coding
exons (exons 2–41) including the exon–
intron boundaries of the ITGB4 revea-
led that the proband was homozygous
for c.953_955del in exon 8 (Figure 2a).
The genomic DNA nucleotides, the
Abbreviations: EB, epidermolysis bullosa; JEB, junctional EB; JEB-PA, JEB with pyloric atresia; ITGA6, a6
integrin subunit; ITGB4, b4 integrin subunit; UPD, uniparental disomy
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